Edwards Lifesciences (EW) Tops Q2 EPS by 6c; Guides Above
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edwards Lifesciences Reports Second Quarter Results
July 26, 2016 4:15 PM EDTIRVINE, Calif., July 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2016.
Second Quarter Highlights:
Sales grew 23.1% to $759.3 million; underlying1 sales were up 21% Global Transcatheter Heart Valve Therapy (THVT) sales grew 48.7%; underlying grew 45% U.S. THVT sales were up 71.5%; underlying grew 66% GAAP EPS was $0.58, an increase of 13.7%; adjusted2 EPS grew 33% to $0.76 2016... More